Patents by Inventor Hans Maag

Hans Maag has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20240025890
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: September 1, 2023
    Publication date: January 25, 2024
    Inventors: William W. TURNER, Lee D. ARNOLD, Hans MAAG, Leping LI, Mark G. BURES, Simon Nicolas HAYDAR, Samson FRANCIS
  • Hepatitis b core protein modulators
    Patent number: 11814376
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: January 4, 2021
    Date of Patent: November 14, 2023
    Assignees: Assembly Biosciences, Inc., Indiana University Research and Technology Corporation
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • TRIAZOLE GLYCOLATE OXIDASE INHIBITORS
    Publication number: 20230143491
    Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.
    Type: Application
    Filed: June 17, 2022
    Publication date: May 11, 2023
    Inventors: Hans MAAG, Miguel Xavier FERNANDES, Robert ZAMBONI, Elham AKBARIROMANI, Marc-Andre BEAULIEU, Yves LEBLANC, Pallavi THAKUR
  • PROCESSES FOR PREPARING TRIAZOLE GLYCOLATE OXIDASE INHIBITORS
    Publication number: 20230129160
    Abstract: The present disclosure provides processes for preparing 1,2,3-tri-azole-4-carboxylic acid related compounds of formulae (I) and (II) via a Suzuki coupling reaction. The Suzuki coupling reaction is achieved by coupling a compound of formula (IV), a boron-containing derivative of 1,2,3-triazole-4-carb oxylate, with a cycloalkyl phenyl halide or sulfonate of formula (V).
    Type: Application
    Filed: January 7, 2021
    Publication date: April 27, 2023
    Inventors: Elham AKBARIROMANI, Pooran CHAND, Sunil Kumar CHOUDHARY, Miguel Xavier FERNANDES, Yves LEBLANC, Hans MAAG, Omkar REVU, Pavan SHEKHAWAT
  • SIGMA LIGAND COMPOUNDS AND USES THEREOF
    Publication number: 20230054070
    Abstract: The present disclosure relates to compounds of Formula (I): and their prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of their preparation. The compounds disclosed herein are useful for modulating Sigma receptors and have antiviral activity, and may also be useful in the treatment and/or prevention of pain disorders, neurological disorders (e.g., Parkinson's disease and Alzheimer's disease), and cancer.
    Type: Application
    Filed: August 12, 2021
    Publication date: February 23, 2023
    Inventors: Remy Luthringer, Nadine Noel, Florent Schmitt, Sandra Werner, Hans Maag, Jay Saoud
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20230044112
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: January 4, 2021
    Publication date: February 9, 2023
    Applicants: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
    Publication number: 20230019129
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: January 21, 2021
    Publication date: January 19, 2023
    Applicants: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: William W. Turner, JR., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • Triazole glycolate oxidase inhibitors
    Patent number: 11401246
    Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.
    Type: Grant
    Filed: July 5, 2019
    Date of Patent: August 2, 2022
    Assignee: CANTERO THERAPEUTICS, INC.
    Inventors: Hans Maag, Miguel Xavier Fernandes, Robert Zamboni, Elham Akbariromani, Marc-Andre Beaulieu, Yves Leblanc, Pallavi Thakur
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20220023311
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: January 14, 2021
    Publication date: January 27, 2022
    Inventors: William W. Turner, Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • TRIAZOLE GLYCOLATE OXIDASE INHIBITORS
    Publication number: 20210403439
    Abstract: The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.
    Type: Application
    Filed: July 5, 2019
    Publication date: December 30, 2021
    Inventors: Hans MAAG, Miguel Xavier FERNANDES, Robert ZAMBONI, Elham AKBARIROMANI, Marc-Andre BEAULIEU, Yves LEBLANC, Pallavi THAKUR
  • GLYCOLATE OXIDASE INHIBITORS AND USE THEREOF
    Publication number: 20210171503
    Abstract: The present invention provides pyrazoles, isoxazoles, isothiazoles, thiadiazoles, and pyridazines according to Formula I as described herein, and pharmaceutically acceptable salts thereof. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described.
    Type: Application
    Filed: December 28, 2018
    Publication date: June 10, 2021
    Inventors: Hans MAAG, Miguel Xavier Fernandes
  • Hepatitis B core protein modulators
    Patent number: 10987360
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: April 27, 2021
    Assignee: Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Hepatitis B core protein modulators
    Patent number: 10968211
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: April 6, 2021
    Assignees: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William W. Turner, Jr., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • Hepatitis B core protein allosteric modulators
    Patent number: 10947224
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 16, 2021
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: William W. Turner, Jr., Lee Daniel Arnold, Hans Maag, Adam Zlotnick
  • Hepatitis B core protein modulators
    Patent number: 10766890
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: September 8, 2020
    Assignees: Assembly Biosciences, Inc., INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION
    Inventors: William Turner, Hans Maag, Samson Francis
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20200131168
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Application
    Filed: May 30, 2019
    Publication date: April 30, 2020
    Inventors: William W. Turner, JR., Lee D. Arnold, Hans Maag, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Samson Francis
  • Hepatitis B core protein modulators
    Patent number: 10392379
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: August 27, 2019
    Assignees: Assembly Biosciences, Inc., Indiana University Research And Technology Corporation
    Inventors: William Turner, Lee Daniel Arnold, Hans Maag, Mark Bures
  • HEPATITIS B CORE PROTEIN MODULATORS
    Publication number: 20190255067
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp.
    Type: Application
    Filed: September 14, 2017
    Publication date: August 22, 2019
    Inventors: William W. Turner, JR., Lee D. Arnold, Leping Li, Mark G. Bures, Simon Nicolas Haydar, Hans Maag, Lynne Bannen
  • Hepatitis B core protein modulators
    Patent number: 10377748
    Abstract: The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: August 13, 2019
    Assignees: Assembly Biosciences, Inc., Indiana University Research And Technology Corporation
    Inventors: William Turner, Lee Daniel Arnold, Hans Maag, Leping Li, Mark Bures, Simon Haydar, Samson Francis
  • Hepatitis B viral assembly effectors
    Patent number: 10273228
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 30, 2019
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.